Immunopathogenesis of systemic lupus erythematosus

Future Rheumatology

Volumn 2, Issue 1, 2007, Pages 93-103

  Mittal, Gayatri ^a   Mason, Lesley ^b   Isenberg, David ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b Division of Medicine   (United Kingdom)

Author keywords

Etiopathogenesis; Morbidity; Mortality; Systemic lupus erythemtosus

Indexed keywords

ABETIMUS; ALPHA INTERFERON; B LYMPHOCYTE RECEPTOR; BELIMUMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CELL ADHESION MOLECULE; COMPLEMENT RECEPTOR; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GAMMA INTERFERON; HYDRALAZINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE BINDING PROTEIN; PLACEBO; PROCAINAMIDE; PROTEIN KINASE LYN; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACCESSORY CELL; ANTIGEN PRESENTATION; APOPTOSIS; B LYMPHOCYTE; CELL INTERACTION; CLINICAL TRIAL; COMPLEMENT DEFICIENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; HEREDITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET IRRADIATION; UNSPECIFIED SIDE EFFECT;

EID: 34249337428     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.1.93     Document Type: Review

References (46)

1. Trager J, Ward MM: Mortality and causes of death in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13(5), 345-351 (2001).
2. Bernatsky S, Boivin JF, Joseph L et al.: Mortality in systemic lupus erythematosus. Arthritis Rheum. 54(8), 2550-2557 (2006).
3. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C: High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch. Intern. Med. 164(1), 77-82 (2004).
4. Kirou Ka, Lee C, George S, Louca K, Peterson MC, Crow MK: Activation of interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52(5), 1491-1503 (2005).
5. Feng X, Wu H, Grossman JM et al.: Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54(9), 2951-2962 (2006).
6. Li QZ, Xie C, Wu T et al.: Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J. Clin. Invest. 115(12), 3428-3439 (2005).
7. Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F: Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cell Immunol. 239(2), 121-128 (2006).
8. Miyara M, Amoura Z, Parizot C et al.: Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 175(12), 8392-8400 (2005).
9. Wong CK, Lit LC, Tam LS, Li EK, Lam CW: Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 44(8), 989-994 (2005).
10. Kawamoto M, Harigai M, Hara M et al.: Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-γ and anti-double-stranded DNA antibody production. Arthritis Res. Ther. 8(3), R62 (2006).
11. Bijl M, Horst G, Limburg PC, Kallenberg CG: Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 60(5), 523-526 (2001).
12. Boumpas DT, Furie R, Manzi S et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48(3), 719-727 (2003).
13. Yurasov S, Tiller T, Tsuiji M et al.: Persistent expression of autoantibodies in SLE patients in remission. J. Exp. Med. 203(10), 2255-2261 (2006).
14. Nagafuchi H, Wakisaka S, Takeba Y, Takeno M, Sakane T, Suzuki N: Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: 'immune previlage'-like state of the autoreactive B cells. Clin. Exp. Rheumatol. 20(5), 625-631 (2002).
15. Sfikakis PP, Boletis JN, Tsokos GC: Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol. 17(5), 550-557 (2005).
16. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44(12), 1542-1545 (2005).
17. Sfikakis PP, Boletis JN, Lionaki S et al.: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open label trial. Arthritis Rheum. 52(2), 501-513 (2005).
18. Smith KG, Jones RB, Burns SM, Jayne DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54(9), 2970-2982 (2006).
19. Dorner T, Kaufmann J, Wegener WA et al.: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8(3), R74 (2006).
20. Alarcon-Segovia D, Tumlin JA, Furie RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum. 48(2), 442-454 (2003).
21. Grammer AC, Fischer R, Lee O, Zhang X, Lipsky PE: Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res. Ther. 6(1), 28-38 (2004).
22. Mackay M, Stanevsky A, Wang T et al.: Selective dysregulation of FcγIIB receptor on memory B cells in SLE. J. Exp. Med. 203(9), 2157-2164 (2006).
23. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA: Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 52(12), 3955-3965 (2005).
24. Becker-Merok A, Nikolaisen C, Nossent HC: B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15(9), 570-576 (2006)
25. Furie R, Lisse J, Merrill JT et al.: Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator (BLyS)) improves or stabilizes SLE activity in a multi-center Phase II trial. Arthritis Rheum. 54, 5258 (2006).
26. + (myeloid) dendritic cells in systemic lupus erythematosus. Clin. Exp. Immunol. 142(1), 84-91 (2005).
27. Koller M, Zwolfer B, Steiner G, Smolen JS, Scheinecker C: Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients. Int. Immunol. 16(11), 1595-1604 (2004).
28. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34(2), 501-537 (2004).
29. Arbuckle MR, McClain MT, Rubertone MV et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349(16), 1526-1533 (2003).
30. Amoura Z, Koutouzov S, Piette JC: The role of nucleosomes in lupus. Curr. Opin. Rheumatol. 12(5), 369-373 (2000).
31. Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA: Is α-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rhuem. 50(3), 866-870 (2004).
32. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA: Anti-Clq antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64(3), 444-448 (2005).
33. Lee YH, Witte T, Momot T et al.: The mannose-binding lectin gene polymorphism and systemic lupus erythematosus: two case-control studies and meta-analysis. Arthritis Rheum. 52(12), 3966-3974 (2005).
34. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr: Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 64(12), 1692-1697 (2005).
35. Means TK; Luster AD: Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann. NY Acad. Sci. 1062, 242-251 (2005).
36. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumour necrosis factor α: findings in open-label and randomised placebo-controlled trials. Arthritis Rheum. 43(11), 2383-2390 (2000).
37. Aringer M, Graninger WB, Steiner G, Smolen JS: Safety and efficacy of tumour necrosis α blockade in systemic lupus erythematosus: an open label study. Arthritis Rheum. 50(10), 316-319 (2004).
38. Dorner T, Lipsky PE: Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity. Clin. Exp. Med. 4(4), 159-169 (2005).
39. Shen N, Tsao BP: Current advances in the human lupus genetics. Curr. Rheumatol. Rep. 6(5), 391-398 (2004).
40. Harley JB, Kelly JA, Kaufman KM: Unraveling the genetics of systemic lupus erythematosus. Springer Semin. Immunopathol. 28(2), 119-130 (2006).
41. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS: Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum. 46(7), 1830-1839 (2002).
42. Adelman MK, Marchalonis JJ: Endogenous retroviruses in systemic lupus erythematosus: candidate lupus viruses. Clin. Immunol. 102(2), 107-116 (2002).
43. Poole BD, Scofield RH, Harley JB, James JA: Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39(1), 63-70 (2006).
44. Finckh A, Cooper GS, Chibnik LB et al.: Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum. 54(11), 3648-3654 (2006).
45. Bengtsson AA, Rylander L, Hagmar L, Nived O, Sturfelt G: Risk factors for developing systemic lupus erythematosus: a case-control study in Southern Sweden. Rheumatology (Oxford) 41(5), 563-571 (2002).
46. Ghaussy NO, Sibbitt WL Jr, Qualls CR: Cigarette smoking, alcohol consumption, and risk of systemic lupus erythematosus: a case-control study. J. Rheumatol. 28(11), 2449-2453 (2001).